Noile-Immune Biotech Profit Margin

Noile-Immune Biotech posts a profit margin of -105437.76% as of June 2026. That compares with -7571.18% in the prior-year period — down 1292.6% year over year. That is below the Healthcare sector average of 19.13%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Noile-Immune Biotech's profit margin was -7571.18%. The latest reading is -105437.76% — a 1292.6% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 19.13% is typical. Noile-Immune Biotech's -105437.76% is lower that level. That is roughly 551227.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Noile-Immune Biotech's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -105437.76% as of June 2026; use YoY and peer views to separate noise from signal.

Context for 4893.T's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 19.13%), and (3) consistency with growth and profitability. This page covers the first two; Noile-Immune Biotech's other metric pages and overview cover the third.